Cetera Trust Company’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$690K Hold
6,250
– – 0.35% 64
2026
Q2
$489K Buy
6,250
+50
+0.8% +$3.41K 0.25% 77
2026
Q1
$401K Hold
6,200
– – 0.23% 85
2025
Q4
$417K Hold
6,200
– – 0.22% 82
2025
Q3
$455K Hold
6,200
– – 0.25% 72
2025
Q2
$323K Buy
6,200
+425
+7% +$24.2K 0.19% 94
2025
Q1
$369K Buy
5,775
+150
+3% +$8.71K 0.23% 73
2024
Q4
$269K Buy
5,625
+85
+2% +$4.36K 0.17% 110
2024
Q3
$317K Hold
5,540
– – 0.19% 99
2024
Q2
$290K Hold
5,540
– – 0.18% 98
2024
Q1
$225K Sell
5,540
-100
-2% -$3.75K 0.14% 146
2023
Q4
$208K Buy
+5,640
New +$212K 0.13% 145

Other funds holding HALO

Cetera Trust Company's HALO Position: Q3 2026 in Review

Cetera Trust Company held its Halozyme (HALO) position steady in Q3 2026 at 6,250 shares worth $690K. The position accounts for 0.35% of the portfolio, ranked #64.

Cetera Trust Company first reported a position in HALO in Q4 2023 and has held it in 12 quarters since. 777 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Cetera Trust Company held 6,250 shares of Halozyme worth $690K as of Q3 2026.
  • Cetera Trust Company left its Halozyme share count unchanged in Q3 2026.
  • Halozyme made up 0.35% of Cetera Trust Company's portfolio in Q3 2026, its #64 holding.
  • Cetera Trust Company first reported a position in Halozyme in Q4 2023 and has held it in 12 quarters since.
  • 777 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Cetera Trust Company's 13F filing for Q3 2026, filed 9 Nov 2026.